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TO THE EDITOR
Vascular anomalies comprise a spec-
trum of lesions subdivided into malfor-
mations and tumors by clinical behavior
and histological features. Vascular
malformations demonstrate slow pro-
gression, whereas vascular tumors proli-
ferate rapidly with marked endo-
thelial turnover (Enjolras et al., 2007).
Deﬁnitive diagnosis can be challeng-
ing, as lesion characteristics may not
conform to existing classiﬁcations.
Hence, many vascular anomalies are
identiﬁed descriptively (Enjolras et al.,
2007). “Lobular capillary hemangioma”
describes a vascular tumor with lobu-
lar architecture, including infantile
hemangiomas (IHs) and other vascular
lesions with lobules of proliferating
endothelial cells, although the term is
commonly used interchangeably for
pyogenic granuloma (PG) (Enjolras
et al., 2007). PGs are benign, sponta-
neous vascular tumors with small
vessels organized in lobules (Giblin
et al., 2007). Approximately 0.5%
of skin nodules and 10% of head and
neck hemangiomas are PGs, which
often develop in children and
adolescents and up to 5% of pregnant
women, although rare congenital,
disseminated cases occur (Giblin et al.,
2007; Browning et al., 2009). Lesions
appear as dome-shaped, bright red or
blue protrusions that grow rapidly and
are prone to hemorrhage (Enjolras et al.,
2007). PGs primarily occur on cuta-
neous or mucosal surfaces of the
head, neck, and upper extremities,
although cases within the gastrointes-
tinal tract, urinary tract, eye, and the
central nervous system have been
reported (Ahuja et al., 2013). Although
infection, trauma, and angiogenic
factor upregulation have been pro-
posed, the etiology of PG remains
unknown (Giblin et al., 2007; Ahuja
et al., 2013).
Before the start of our investigation, the
Yale Human Investigation Committee
approved the study protocol, and all
subjects provided written, informed con-
sent. To identify somatic mutations driv-
ing the formation of lobular vascular
tumors, we used pairwise whole-exome
sequencing (WES) of blood and affected
tissue in two patients. The ﬁrst patient
(VASC100) was a 5-year-old boy with a 1-
cm compressible, pulsatile tumor on the
left helix that had enlarged and reddened
over 4 months (Figure 1a). Histologically,
it contained lobules of benign-appearing
endothelial cells (Figure 1b and c). The
second patient (VASC101) was a healthy
male infant who had a pedunculated
vascular nodule on the medial left lower
eyelid at birth undetected by prenatal
ultrasound (Figure 1d). Despite predni-
sone and propranolol treatment, the
lesion grew rapidly. Histopathology
showed lobules of small caliber capil-
laries, extensive necrosis, and intervening
foci with dilated vessels, some with valves
(Figure 1e and f).
After pairwise WES, somatic muta-
tions were identiﬁed (Supplementary
Materials and Methods online). A het-
erozygous KRAS c.35G4A, p.G12D
mutation and a heterozygous NRAS
c.181C4A, p.Q61K mutation were
found in VASC100 and VASC101
tumors, respectively (Table 1 and Sup-
plementary Tables S1 and S2 online and
Supplementary Figure S1 online). These
mutations were conﬁrmed by means of
Sanger sequencing (Supplementary
Figure S2 online). Neither data set had
mutations in genes that were previously
identiﬁed in vascular tumors or malfor-
mations, including TEK, RASA1, CCM1-
/2/3, GLMN, VEGRF3, FOXC2, SOX18,
ACVRLK1, MADH4, and ENG (Ye et al.,
2011). No evidence of secondary
somatic variants or regions of loss of
heterozygosity was found, suggesting that
both cases are true somatic RASopathies
(Supplementary Figure S3 online).
Recognizing that PGs share the lob-
ular architecture found in VASC100 and
101 tumors, we screened paired
lesional and normal tissue of 40 archi-
val PG samples from adolescent
patients (age o18) for RAS mutation
via Sanger sequencing. This age range
was selected as our exome cases were
young children, and PGs commonly
affect this age group. Four (4/40, 10%,
VASC102, VASC103, VASC104, and
VASC105) had somatic RAS mutations
(Table 1) and all showed lobules of
small caliber vessels (Supplementary
Figures S4a–d and S5a–d online). Both
VASC102 and VASC104 PGs had a
heterozygous c.182A4G, p.Q61R
mutation in HRAS, whereas VASC103
and VASC105 PGs had a heterozygous
c.145G4A, p.E49K and a heterozygous
c.37G4A, p.G13S mutation in HRAS,
respectively (Table 1 and Supplemen-
tary Figures S4e, f and S5e, f online).
VASC105 had additional heterozygous
HRASmutations c.44G4A, p.G15D and
c.100C4T, p.P34S of unknown signi-
ﬁcance. The erythrocyte-type glucose
transporter GLUT1 is a speciﬁc marker
of IHs (Leon-Villapalos et al., 2005),
but immunoreactivity was negative in
all six of our cases (Supplementary
Figure S6a–f online).
Previously identiﬁed somatic muta-
tions in vascular tumors or malfor-
mations have involved key angiogenic
players such as TEK, a tyrosine
kinase involved in vascular remodeling,
and the vascular endothelial growth
factor receptor (VEGFR) (Ye et al., 2011).
Although somatic mutation in RAS has
not been reported in human PG or
vascular tumors, RAS signaling is asso-
ciated with angiogenesis and vascular
proliferation (Kranenburg et al., 2004).
Tumor cells that express activated KRAS
show increased VEGF synthesis, by stabi-
lization of VEGF mRNA or increasedAccepted article preview online 19 February 2015; published online 12 March 2015
Abbreviations: IH, infantile hemangioma; MAPK, mitogen-activated protein kinase; PG, pyogenic
granuloma; VEGF, vascular endothelial growth factor; WES, whole-exome sequencing
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phosphorylation of HIF-1a, a transcrip-
tion factor for VEGF (Kranenburg et al.,
2004). Transgenic KRAS G12D mice
spontaneously develop multiple vascular
tumors, with endothelial cells demon-
strating an RAS-dependent increase in
VEGF and Flk-1 mRNA (Fisher et al.,
2001). RAS mutant endothelial cells
acquire an angiogenic phenotype, inclu-
ding membrane rufﬂing, branching
morphogenesis, increased DNA syn-
thesis, and cell migration (Meadows
et al., 2004). Constitutively active HRAS
G12V ﬁbroblasts and KRAS mutant intes-
tinal epithelial cells demonstrate enhan-
ced expression of cyclooxygenase-2,
which increases the synthesis of pro-
angiogenic cytokines and prostaglandins,
further stimulating these factors via posi-
tive feedback (Kranenburg et al., 2004). For
archival PG lesions without RAS muta-
tions, it is possible that they harbor muta-
tions in distinct regulators of angiogenesis,
or other genes in the RAS pathway.
Germline RASopathies provide
further evidence for Ras-mitogen-
activated protein kinase (MAPK) activity
in vascular tumorigenesis. PG occurs in
Costello syndrome owing to HRAS
mutations (Morice-Picard et al., 2013),
and a congenital ulcerating heman-
gioma was reported in a case of
cardio-facio-cutaneous syndrome with
a germline KRAS mutation (Tang et al.,
2007). In addition, germline mutations
in RASA1, a RAS p21 protein activator,
cause capillary malformation–arterio-
venous malformation (CM–AVM),
which features an increased number of
dermal capillaries (Eerola et al., 2003).
Our reported RAS mutations have
been found in cancer, including codon
12, 13, and 61 mutations, which are
well-established hotspots for constitutive
activation of Ras-MAPK signaling. The
HRAS E49K variant in VASC103 is at a
less commonly implicated site; to date,
mutations at this position have only been
Figure 1. Clinical and histological features of vascular tumors. (a–c) VASC100, a 5-year-old boy, who presented with a 1-cm reddish lesion on the left ear.
Histopathology demonstrates a lobular organization of small caliber vessels. (d–f) VASC101, a male infant with a large pedunculated vascular nodule involving
the left lower eyelid, which was present since birth. The tumor was difﬁcult to classify, but there were foci of lobules of small capillaries, necrosis (not shown), and
intervening areas composed of more dilated valvular vessels (not shown). (b, e) Magniﬁcation × 4, bar=100 μm; (c, f) × 10, bar= 100 μm.
Table 1. RAS mutation identiﬁed in six vascular tumors
Patient Diagnosis Age/sex Site of lesion Gene Base change Protein change Method
VASC100 Vascular tumor 5/M Ear KRAS G4A G12D WES
VASC101 Vascular tumor 0/M Lower eyelid NRAS C4A Q61K WES
VASC102 PG 12/M Back HRAS A4G Q61R SS
VASC103 PG 14/M Abdomen HRAS G4A E49K SS
VASC104 PG 2/F Cheek HRAS A4G Q61R SS
VASC105 PG 15/M Back HRAS G4A G13S SS
Abbreviations: A, adenine; C, cytosine; F, female; G, guanine; M, male; PG, pyogenic granuloma; SS, Sanger sequencing; WES, whole-exome sequencing.
Patient ID, histopathological diagnosis, age at the time of presentation, sex, site of lesion, mutation information (gene, base change, and amino-acid change),
and method of detection are presented.
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reported in somatic NRAS- and KRAS-
driven neoplasms (Reifenberger et al.,
2004; Palomba et al., 2012).
Our identiﬁcation of somatic RAS
mutations in vascular tumors has clinical
relevance. Current therapies against
these lesions are limited to steroids and
β-blockers, which achieve mixed results,
often limited to tumor size reduction
without resolution (Wine Lee et al.,
2014). Some infantile vascular tumors,
such as VASC101, are unresponsive to
such interventions (Wine Lee et al., 2014).
These cases may harbor RAS mutations,
and might respond to farnesyl transferase
inhibitors or Raf/Mek/Erk inhibitors, which
block signaling upstream or downstream
of RAS. The ﬁnding that RAS mutation
drives vascular tumors provides potential
opportunities to develop targeted therapies
for current drug-resistant lesions.
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TO THE EDITOR
Chronic diabetic ulcers remain an
intractable clinical problem that leads
to signiﬁcant morbidity and mortality
throughout the world. Selection of an
appropriate treatment strategy that is
individually tailored to each patient
from the hundreds of choices available
in the market is critical to success in
wound care. However, there is cur-
rently no objective measurement that
can reliably predict healing outcome in
chronic diabetic ulcers, making such aAccepted article preview online 3 February 2015; published online 26 February 2015
Abbreviations: ANOVA, analysis of variance; GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
MMP, matrix metalloprotease
1700 Journal of Investigative Dermatology (2015), Volume 135
YH Lim et al.
Gene Expression Signature in Human Diabetic Ulcers
